![](https://endpts.com/wp-content/uploads/2022/11/Phil-LHuillier-CatalYm.jpg)
Phil L’Huillier, CatalYm CEO
German biotech CatalYm raises $150M to repurpose obesity target for cancer
CatalYm has racked up $150 million in an oversubscribed Series D to advance its antibody drug that neutralizes GDF15 — a target previously explored by other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.